Story perspectives

CSL Behring Cuts 3,000 Jobs, Spins Off Vaccine Division

8/20/2025

35 7

Summary

Story summary

CSL Behring will cut 3,000 jobs and spin off its vaccine division amid biotech industry volatility.
The company targets annual savings of $500-$550 million over three years, with one-time costs of $560-$770 million.
Closure of 22 underperforming plasma centers will affect up to 15% of the workforce.
The restructuring aims to improve operational efficiency and concentrate on core strengths.
Completion of the separation process is expected by early 2026.

1 of 1

Story summary

CSL Behring will cut 3,000 jobs and spin off its vaccine division amid biotech industry volatility.
The company targets annual savings of $500-$550 million over three years, with one-time costs of $560-$770 million.
Closure of 22 underperforming plasma centers will affect up to 15% of the workforce.
The restructuring aims to improve operational efficiency and concentrate on core strengths.
Completion of the separation process is expected by early 2026.